Leptin, adiponectin, and resistin may play an important role in the development of lipodystrophy (LD) in HIV/AIDS patients. The aim of this study was to correlate levels of leptin, adiponectin, and resistin between HIV/AIDS patients with LD and without lipodystrophy (non-LD), as well as between subgroups of LD [lipoatrophy (LA), lipohypertrophy (LH), and mixed fat redistribution (MFR)] and non-LD patients.
Methods:
Cross-sectional study of 66 HIV/AIDS patients. Serum levels of leptin, adiponectin, and resistin were measured. The associations between adipocytokine levels and metabolic variables were estimated by Spearman correlation. Analysis of covariance with bootstrapping method was used to examine the relationship between adiponectin and leptin and lipodystrophy categories.
Results:
The LD was observed in 29 (44%) patients, while 15 (52%) of them had LA, 4 (14%) had LH, and 10 (34%) patients had MFR. No significant differences regarding leptin, adiponectin, and resistin levels, between LD and non-LD patients, were observed. LH patients had significantly higher levels of leptin and adiponectin in comparison with non-LD patients (P = 0.039, P = 0.011, respectively). Within the LD group, LA patients had significantly lower levels of leptin (LA vs. LH, P = 0.020; LA vs. MFR, P = 0.027), while LH patients had significantly higher levels of adiponectin (LH vs. LA, P = 0.027; LH vs. MFR, P = 0.028). Correlation of adiponectin with LD remains significant in the LH subgroup after adjustment for age, body mass index, cystatin-C, plasminogen activator inhibitor-1 (PAI-1), and interferon gamma (IFN-γ) (P = 0.001).
Conclusions:
Adiponectin and leptin levels differ significantly between LH patients and non-LD patients, as well as between the LD subgroups. Adiponectin may be a more useful marker of LD in HIV/AIDS patients.
Get full access to this article
View all access options for this article.
References
1.
PalellaFJJr., BakerRK, MoormanAC, et al.Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr, 2006; 43:27–34.
2.
FreitasP, CarvalhoD, SoutoS, et al.Impact of lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients. BMC Infect Dis, 2011; 11:246.
3.
PlankeyM, BacchettiP, JinC, et al.Self-perception of body fat changes and HAART adherence in the Women's Interagency HIV Study. AIDS Behav, 2009; 13:53–59.
4.
BlüherM. Adipokines—Removing road blocks to obesity and diabetes therapy. Mol Metab, 2014; 3:230–240.
5.
ParuthiJ, GillN, MantzorosCS. Adipokines in the HIV/HAART-associated lipodystrophy syndrome. Metabolism, 2013; 62:1199–1205.
6.
AramaV, MunteanuDI, CercelAS, et al.Lipodystrophy syndrome in HIV treatment-multiexperienced patients: Implication of resistin. J Endocrinol Invest, 2014; 37:533–539.
7.
FreitasP, CarvalhoD, SantosAC, et al.Adipokines, hormones related to body composition, and insulin resistance in HIV fat redistribution syndrome. BMC Infect Dis, 2014; 14:347.
8.
KosmiskiLA, BaccettiP, KotlerDP, et al.Relationship of fat distribution with adipokines in human immunodeficiency virus infection. J Clin Endocrinol Metab, 2008; 93:216–224.
9.
CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep, 1992; 41:1–19.
10.
AlbertiKG, EckelRH, GrundySM, et al.Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the study of Obesity. Circulation, 2009; 120:1640–1645.
11.
BedimoRJ. Body fat abnormalities in patients with HIV: Progress and challenges. J Int Assoc Physicians AIDS Care (Chic), 2008; 7:292–305.
12.
PadillaS, MasiaM, GarciaN, et al.Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. BMC Infect Dis, 2011; 11:40.
13.
LikataviciusG, van de LaarMJ. HIV infection and AIDS in the European Union and European Economic Area. Euro Surveill 2011, 2010; 16:20030.
14.
BeloS, SantosAC, MadureiraA, et al.IL-4 and IL-6 levels and adipose tissue distribution in HIV-1 patients under antiretroviral therapy. J Endocrinol Invest, 2015; 38:779–784.
15.
FinkelsteinJ, GalaP, RochfordR, et al.HIV/AIDS and lipodystrophy: Implications for clinical management in resource-limited settings. J Int AIDS Soc, 2015; 18:19033.
16.
MargolisAM, HeverlingH, PhamPA, et al.A review of the toxicity of HIV medications. J Med Toxicol, 2014; 10:26–39.
17.
DragovicG, SmithCJ, JevtovicDJ, et al.Comparison of nucleoside reverse transcriptase inhibitor use as part of first-line therapy in a Serbian and a UK clinic. HIV Clin Trials, 2009; 10:306–313.
18.
OralEA, ChanJL. Rationale for leptin-replacement therapy for severe lipodystrophy. Endocr Pract, 2010; 16:324–333.
19.
CalmyA, Gayet-AgeronA, MontecuccoF, et al.HIV increases markers of cardiovascular risk: Results from a randomized, treatment interruption trial. AIDS, 2009; 23:929–939.
20.
MynarcikDC, CombsT, McNurlanMA, et al.Adiponectin and leptin values in HIV-infected subjects with insulin resistance and body fat redistribution. J Acquir Immune Defic Syndr, 2002; 31:514–520.
21.
DzwonekAB, NovelliV, ScwenkA, et al.Serum leptin concentrations and fat redistribution in HIV-1-infected children on highly active antiretroviral therapy. HIV Med, 2007; 8:433–438.
22.
NagyGS, TsiodrasS, MartinLD, et al.Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis, 2003; 36:795–802.
23.
KelesidisT, KelesidisI, ChouS, et al.Narrative review: The role of leptin in human physiology: Emerging clinical applications. Ann Intern Med, 2010; 152:93–100.
24.
LangkiledeA, PetersenJ, HenriksenJH, et al.Leptin, IL-6, and suPAR reflect distinct inflammatory changes associated with adiposity, lipodystrophy and low muscle mass in HIV-infected patients and controls. Immun Ageing, 2015; 12:9.
25.
LiuP, SuiS, XuD, et al.Clinical analysis of the relationship between cystatin C and metabolic syndrome in the elderly. Rev Port Cardiol, 2014; 33:411–416.
26.
JonesSP, WaittC, SuttonR, et al.Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes. AIDS, 2008; 22:1293–1298.
27.
VernochetC, AzoulayS, DuvalD, et al.Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines. J Biol Chem, 2005; 280:2238–2243.
28.
LuoL, ZhangL, TaoM, et al.Adiponectin and leptin levels in Chinese patients with HIV-related lipodystrophy: A 30-month prospective study. AIDS Res Hum Retroviruses, 2009; 25:1265–1272.
29.
TongQ, SankaleJL, HadiqanCM, et al.Regulation of adiponectin in human immunodeficiency virus-infected patients: Relationship to body composition and metabolic indices. J Clin Endocrinol Metab, 2003; 88:1559–1564.
30.
AddyCL, GavrilaA, TsiodrasS, et al.Hypoadiponectemia is associated with insulin resistence, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab, 2003; 88:627–636.
31.
YamamotoS, MatsushitaY, NakagawaT, et al.Circulating adiponectin levels and risk of type 2 diabetes in the Japanese. Nutr Diabetes, 2014; 4:e130.
32.
MasiaM, PadillaS, GarciaN, et al.Endothelial function is impaired in HIV-infected patients with lipodystrophy. Antivir Ther, 2010; 15:101–110.
33.
BarbD, WadhwaSG, KratzschJ, et al.Circulating resistin levels are not associated with fat redistribution, insulin resistance, or metabolic profile in patients with the highly active antiretroviral therapy-induced metabolic syndrome. J Clin Endocrinol Metab, 2005; 90:5324–5328.
34.
SilhaJV, KrsekM, SkrhaJV, et al.Plasma resistin, adiponectin and leptin levels in lean and obese subjects: Correlation with insulin resistance. Eur J Endocrinol, 2003; 149:331–335.
35.
EscoteX, MirandaM, VelosoS, et al.Lypodystrophy and insulin resistance in combination antiretroviral treated HIV-1 infected patients: Implication of resistin. J Acquir Immune Defic Syndr, 2011; 57:16–23.
36.
RanadeK, GeeseWJ, NoorM, et al.Genetic analysis implicates resistin in HIV lipodystrophy. AIDS, 2008; 22:1561–1568.
37.
NogueirasR, NovelleMG, VazquezMJ, et al.Resistin: Regulation of food intake, glucose homeostasis and lipid metabolism. Endocr Dev, 2010; 17:175–184.
38.
BonnetE. New and emerging agents in the management of lipodystrophy in HIV-infected patients. HIV AIDS (Auckl), 2010; 2:167–178.
39.
TaoMM, ZhangL, QiuZF, et al.Adipokines and highly active antiretroviral therapy related lipodystrophy: Clinical study of 52 cases. Zhonghua Yi Xue Za Zhi, 2009; 89:867–871.
40.
RizviAA, NikolicD, SallamHS, et al.Adipokines and lipoproteins: Modulation by antihyperglicemic and hypolipidemic agents. Metab Syndr Relat Disord, 2014; 12:1–10.
41.
HsuCS, LiuWL, ChaoYC, et al.Adipocytokines and liver fibrosis stages with chronic hepatitis virus infection. Hepatol Int, 2015; 9:231–242.
